Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

NAMS

NewAmsterdam Pharma Comp... (NAMS)

NewAmsterdam Pharma Company NV
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:NAMS
일자시간출처헤드라인심볼기업
2024/05/2121:00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/05/0921:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/05/0405:01GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/05/0221:00GlobeNewswire Inc.NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024NASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/04/0921:00GlobeNewswire Inc.NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/04/0121:00GlobeNewswire Inc.NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/03/2521:00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/03/1221:00GlobeNewswire Inc.NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/02/2822:00GlobeNewswire Inc.NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/02/2622:00GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/02/1412:40GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/02/1406:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/02/0206:01GlobeNewswire Inc.NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/01/0822:00GlobeNewswire Inc.NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of DirectorsNASDAQ:NAMSNewAmsterdam Pharma Company NV
2024/01/0422:00GlobeNewswire Inc.NewAmsterdam Pharma Announces 2024 Strategic PrioritiesNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/11/1322:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/10/2321:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/09/2120:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 MutationNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/09/2021:00GlobeNewswire Inc.NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/08/1505:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/08/0720:15GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/07/2605:01GlobeNewswire Inc.NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/06/1005:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/06/0712:25GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/06/0705:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/06/0520:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese PatientsNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/06/0401:15GlobeNewswire Inc.NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023NASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/05/3121:00GlobeNewswire Inc.NewAmsterdam Pharma to Present at Jefferies Healthcare ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/05/2321:00GlobeNewswire Inc.NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023NASDAQ:NAMSNewAmsterdam Pharma Company NV
2023/05/0821:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
 검색 관련기사 보기:NASDAQ:NAMS